Vermont Bills Would Require 340B Hospitals to Report Drug Discount Savings and Spending
Companion bills filed this month in the Vermont House and Senate would require hospitals to report how much money they save through the 340B program
Read More »Articles by : Tom Mirga, Editor at Large
Another New Study of Differences in Cancer Drug Spending Could Have 340B Implications
On Friday, the nonpartisan Medicare Payment Advisory Commission (MedPAC) made headlines (see story below) when its staff said it could find no link between evidence of 340B
Read More »Breaking News
Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts
Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts
Medicare Payment Advisory Commission (MedPAC) researchers were “unable to attribute” evidence of higher drug spending at 340B hospitals on two types of
Read More »(Editor’s note: The Medicare Payment Advisory Commission (MedPAC) tomorrow will consider a staff analysis of “whether the availability of 340B drug discounts creates incentives to choose more expensive products in some cases and the resulting impact on Medicare patients’ cost-share
Read More »MedPAC Will Weigh in on Whether 340B Causes Hospitals to Use More Expensive Drugs
The Medicare Payment Advisory Commission (MedPAC) will hear from its staff on Jan. 17 about whether the 340B program gives participating hospitals an incentive to
Read More »Breaking News
BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility
BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility
The Health Resources and Services Administration’s (HRSA) oversight of 340B private, nonprofit hospitals should be significantly strengthened, the Government Accountability Office (GAO) found in a report released
Read More »Breaking News
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says
The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts
Read More »BREAKING: HRSA Awards 340B Prime Vendor Agreement to Apexus
The Health Resources and Services Administration (HRSA) announced this morning that it has awarded the 340B Prime Vendor Agreement to Apexus LLC after a competitive bid process.
“The 340B Prime Vendor
Read More »Breaking News
BREAKING: Drugmaker Xspire Owes 340B Refunds
Greetings
Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.
BREAKING: Drugmaker Xspire Owes 340B Refunds
Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds
Read More »